Webinar Date/Time: Thu, May 22, 2025 11:00 AM EDT
Explore OSD market trends, key challenges, CDMO strategies for bioavailability, and future advances in drug delivery.
Register Free: https://www.pharmtech.com/pt_w/patient-preference
Event Overview:
Solid dosage drug formulations are becoming increasingly popular among patient populations, but there are challenges for developers. This episode of Drug Digest identifies what those challenges are, what are currently some of the most frequently sought-after expert techniques, how CDMOs can leverage their experience in performing those techniques to improve oral solid dosage bioavailability, and what the future holds in terms of advancements in OSD drug delivery.
Interviews featuring:
This episode of Drug Digest is sponsored by:
Key Learning Objectives:
Who Should Attend:
Speaker:
Adi Kaushal
Director and Technology Head for Bioavailability Enhancement
Lonza
Adi Kaushal is the Director and Technology Head for Bioavailability Enhancement at Lonza Bend. He has been with Lonza since 2010. Adi is responsible for overall BAE technology strategy and progression of customer programs from feasibility to commercialization. Adi’s group of experienced scientists and engineers are engaged in bringing new BAE technologies to product development, customer-centric advancements, and continuous improvement of Lonza internal systems. Adi also supports collaboration with internal R&D within the Lonza Small Molecules business unit.
Register Free: https://www.pharmtech.com/pt_w/patient-preference
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.